{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:20:35Z","timestamp":1792686035680,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The plasma soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker for focal segmental glomerulosclerosis (FSGS), but its value is under discussion because of ambiguous results arising from different ELISA methods in previous studies. The aim of this study was to compare diagnostic performance of two leading suPAR ELISA kits and examine four objectives in 146 subjects: (1) plasma suPAR levels according to glomerular disease (primary, secondary and recurrent FSGS after kidney transplantation, other glomerulonephritis) and in healthy controls; (2) suPAR levels based on glomerular filtration rate; (3) sensitivity and specificity of suPAR for FSGS diagnosis and determination of optimal cut-offs; (4) suPAR as prognostic tool. Patients with FSGS showed significant higher suPAR values than patients with other glomerulonephritis and healthy individuals. This applied to subjects with and without chronic kidney disease. Although both suPARnostic\u2122 assay and Quantikine Human uPAR ELISA Kit exerted high sensitivity and specificity for FSGS diagnosis, their cut-off values of 4.644\u2009ng\/mL and 2.789\u2009ng\/mL were significantly different. Higher suPAR was furthermore predictive for progression to end-stage renal disease. In summary, suPAR values must be interpreted in the context of population and test methods used. Knowing test specific cut-offs makes suPAR a valuable biomarker for FSGS.<\/jats:p>","DOI":"10.1038\/s41598-019-50405-8","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T06:02:51Z","timestamp":1569304971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-6120","authenticated-orcid":false,"given":"Wolfgang","family":"Winnicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gere","family":"Sunder-Plassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcrkan","family":"Seng\u00f6lge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammon","family":"Handisurya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Herkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kornauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4491-0562","authenticated-orcid":false,"given":"Bernhard","family":"Bielesz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljko","family":"Kiki\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahra","family":"Pajenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4607-5329","authenticated-orcid":false,"given":"Thomas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Schairer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"key":"50405_CR1","doi-asserted-by":"crossref","unstructured":"Chen, J. S. et al. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models. J Biomed Sci 23 (2016).","DOI":"10.1186\/s12929-016-0242-7"},{"key":"50405_CR2","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.2215\/CJN.06720810","volume":"5","author":"C Ponticelli","year":"2010","unstructured":"Ponticelli, C. & Glassock, R. J. Posttransplant Recurrence of Primary Glomerulonephritis. Clin J Am Soc Nephro 5, 2363\u20132372 (2010).","journal-title":"Clin J Am Soc Nephro"},{"key":"50405_CR3","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.transproceed.2015.03.048","volume":"47","author":"J Jin","year":"2015","unstructured":"Jin, J., Li, Y. W. & He, Q. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels. Transpl P 47, 1760\u20131765 (2015).","journal-title":"Transpl P"},{"key":"50405_CR4","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1056\/NEJM199604043341402","volume":"334","author":"VJ Savin","year":"1996","unstructured":"Savin, V. J. et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. New Engl J Med 334, 878\u2013883 (1996).","journal-title":"New Engl J Med"},{"key":"50405_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/ckj\/sfv090","volume":"8","author":"T Wada","year":"2015","unstructured":"Wada, T. & Nangaku, M. A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues. Clin Kidney J 8, 708\u2013715 (2015).","journal-title":"Clin Kidney J"},{"key":"50405_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1432-2277.2004.tb00420.x","volume":"17","author":"JK Deegens","year":"2004","unstructured":"Deegens, J. K., Andresdottir, M. B., Croockewit, S. & Wetzels, J. F. Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int 17, 151\u2013157 (2004).","journal-title":"Transpl Int"},{"key":"50405_CR7","first-page":"32","volume":"22","author":"SW Zimmerman","year":"1984","unstructured":"Zimmerman, S. W. Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 22, 32\u201338 (1984).","journal-title":"Clin Nephrol"},{"key":"50405_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1056\/NEJM200102013440517","volume":"344","author":"MJ Kemper","year":"2001","unstructured":"Kemper, M. J., Wolf, G. & Muller-Wiefel, D. E. Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 344, 386\u2013387 (2001).","journal-title":"N Engl J Med"},{"key":"50405_CR9","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1056\/NEJMc1202500","volume":"366","author":"L Gallon","year":"2012","unstructured":"Gallon, L., Leventhal, J., Skaro, A., Kanwar, Y. & Alvarado, A. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med 366, 1648\u20131649 (2012).","journal-title":"N Engl J Med"},{"key":"50405_CR10","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/20469047.2017.1374003","volume":"37","author":"ML Downie","year":"2017","unstructured":"Downie, M. L., Gallibois, C., Parekh, R. S. & Noone, D. G. Nephrotic syndrome in infants and children: pathophysiology and management. Paediatr Int Child Health 37, 248\u2013258 (2017).","journal-title":"Paediatr Int Child Health"},{"key":"50405_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.trsl.2015.03.002","volume":"166","author":"M Sharma","year":"2015","unstructured":"Sharma, M. et al. Janus kinase 2\/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. Transl Res 166, 384\u2013398 (2015).","journal-title":"Transl Res"},{"key":"50405_CR12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/path.4149","volume":"229","author":"JJ Harris","year":"2013","unstructured":"Harris, J. J. et al. Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1. J Pathol 229, 660\u2013671 (2013).","journal-title":"J Pathol"},{"key":"50405_CR13","doi-asserted-by":"publisher","first-page":"256ra136","DOI":"10.1126\/scitranslmed.3008538","volume":"6","author":"M Delville","year":"2014","unstructured":"Delville, M. et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med 6, 256ra136 (2014).","journal-title":"Sci Transl Med"},{"key":"50405_CR14","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/nm.2411","volume":"17","author":"C Wei","year":"2011","unstructured":"Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17, 952\u2013960 (2011).","journal-title":"Nat Med"},{"key":"50405_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00441-017-2635-7","volume":"369","author":"E Hahm","year":"2017","unstructured":"Hahm, E., Peev, V. & Reiser, J. Extrarenal determinants of kidney filter function. Cell Tissue Res 369, 211\u2013216 (2017).","journal-title":"Cell Tissue Res"},{"key":"50405_CR16","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00424-017-2026-7","volume":"469","author":"M Zeier","year":"2017","unstructured":"Zeier, M. & Reiser, J. suPAR and chronic kidney disease-a podocyte story. Pflugers Arch 469, 1017\u20131020 (2017).","journal-title":"Pflugers Arch"},{"key":"50405_CR17","doi-asserted-by":"crossref","unstructured":"Konigshausen, E. & Sellin, L. Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates. Biomed Res Int (2016).","DOI":"10.1155\/2016\/3765608"},{"key":"50405_CR18","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1007\/s00134-012-2613-1","volume":"38","author":"Y Backes","year":"2012","unstructured":"Backes, Y. et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 38, 1418\u20131428 (2012).","journal-title":"Intensive Care Med"},{"key":"50405_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/MCG.0b013e31822da19d","volume":"46","author":"ML Berres","year":"2012","unstructured":"Berres, M. L., Schlosser, B., Berg, T., Trautwein, C. & Wasmuth, H. E. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol 46, 334\u2013338 (2012).","journal-title":"J Clin Gastroenterol"},{"key":"50405_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.58.8.488","volume":"58","author":"O Slot","year":"1999","unstructured":"Slot, O., Brunner, N., Locht, H., Oxholm, P. & Stephens, R. W. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 58, 488\u2013492 (1999).","journal-title":"Ann Rheum Dis"},{"key":"50405_CR21","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/clinchem\/43.10.1868","volume":"43","author":"RW Stephens","year":"1997","unstructured":"Stephens, R. W. et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43, 1868\u20131876 (1997).","journal-title":"Clin Chem"},{"key":"50405_CR22","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1681\/ASN.2012030302","volume":"23","author":"CL Wei","year":"2012","unstructured":"Wei, C. L. et al. Circulating suPAR in Two Cohorts of Primary FSGS. J Am Soc Nephrol 23, 2051\u20132059 (2012).","journal-title":"J Am Soc Nephrol"},{"key":"50405_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1053\/j.ajkd.2003.10.024","volume":"43","author":"VD D\u2019Agati","year":"2004","unstructured":"D\u2019Agati, V. D., Fogo, A. B., Bruijn, J. A. & Jennette, J. C. Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis 43, 368\u2013382 (2004).","journal-title":"Am J Kidney Dis"},{"key":"50405_CR24","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/ndt\/gfk037","volume":"21","author":"K Amann","year":"2006","unstructured":"Amann, K. & Haas, C. S. What you should know about the work-up of a renal biopsy. Nephrol Dial Transpl 21, 1157\u20131161 (2006).","journal-title":"Nephrol Dial Transpl"},{"key":"50405_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nrneph.2014.216","volume":"11","author":"AB Fogo","year":"2015","unstructured":"Fogo, A. B. Causes and pathogenesis of focal segmental glomerulosclerosis. Nature Reviews Nephrology 11, 76\u201387 (2015).","journal-title":"Nature Reviews Nephrology"},{"key":"50405_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.12688\/f1000research.10510.1","volume":"6","author":"V Peev","year":"2017","unstructured":"Peev, V., Hahm, E. & Reiser, J. Unwinding focal segmental glomerulosclerosis. F1000Res 6, 466 (2017).","journal-title":"F1000Res"},{"key":"50405_CR27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/ki.2013.505","volume":"85","author":"B Meijers","year":"2014","unstructured":"Meijers, B. et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 85, 636\u2013640 (2014).","journal-title":"Kidney Int"},{"key":"50405_CR28","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/ki.2012.32","volume":"81","author":"RJ Maas","year":"2012","unstructured":"Maas, R. J., Wetzels, J. F. & Deegens, J. K. Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int 81, 1043\u20131044 (2012).","journal-title":"Kidney Int"},{"key":"50405_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/ki.2013.546","volume":"85","author":"A Sinha","year":"2014","unstructured":"Sinha, A. et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int 85, 649\u2013658 (2014).","journal-title":"Kidney Int"},{"key":"50405_CR30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/ki.2013.513","volume":"85","author":"RJ Maas","year":"2014","unstructured":"Maas, R. J., Wetzels, J. F. & Deegens, J. K. Serum suPAR concentrations in patients with focal segmental glomerulosclerosis with end-stage renal disease. Kidney Int 85, 711 (2014).","journal-title":"Kidney Int"},{"key":"50405_CR31","doi-asserted-by":"crossref","unstructured":"Hayek, S. S. et al. Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol (2019).","DOI":"10.1681\/ASN.2018121227"},{"key":"50405_CR32","first-page":"5679518","volume":"2019","author":"JM Lee","year":"2019","unstructured":"Lee, J. M. et al. Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis. J Immunol Res 2019, 5679518 (2019).","journal-title":"J Immunol Res"},{"key":"50405_CR33","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1056\/NEJMoa1506362","volume":"373","author":"SS Hayek","year":"2015","unstructured":"Hayek, S. S. et al. Soluble Urokinase Receptor and Chronic Kidney Disease. New Engl J Med 373, 1916\u20131925 (2015).","journal-title":"New Engl J Med"},{"key":"50405_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-12-81","volume":"12","author":"J Huang","year":"2014","unstructured":"Huang, J. et al. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med 12, 81 (2014).","journal-title":"BMC Med"},{"key":"50405_CR35","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150, 604\u2013612 (2009).","journal-title":"Ann Intern Med"},{"key":"50405_CR36","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1002\/sim.4509","volume":"31","author":"X Liu","year":"2012","unstructured":"Liu, X. Classification accuracy and cut point selection. Stat Med 31, 2676\u20132686 (2012).","journal-title":"Stat Med"},{"key":"50405_CR37","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/bimj.200410135","volume":"47","author":"R Fluss","year":"2005","unstructured":"Fluss, R., Faraggi, D. & Reiser, B. Estimation of the Youden Index and its associated cutoff point. Biom J 47, 458\u2013472 (2005).","journal-title":"Biom J"},{"key":"50405_CR38","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/jca.21538","volume":"32","author":"H Schenk","year":"2017","unstructured":"Schenk, H. et al. Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb. J Clin Apher 32, 444\u2013452 (2017).","journal-title":"J Clin Apher"},{"key":"50405_CR39","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1681\/ASN.2014030257","volume":"25","author":"J Reiser","year":"2014","unstructured":"Reiser, J. & Chapman, H. Soluble Urokinase-Type Plasminogen Activator Receptor in FSGS: Stirred but Not Shaken. Journal of the American Society of Nephrology 25, 1611\u20131613 (2014).","journal-title":"Journal of the American Society of Nephrology"},{"key":"50405_CR40","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/ki.2014.346","volume":"87","author":"JM Spinale","year":"2015","unstructured":"Spinale, J. M. et al. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int 87, 564\u2013574 (2015).","journal-title":"Kidney Int"},{"key":"50405_CR41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0002-9343(92)90267-F","volume":"92","author":"M Artero","year":"1992","unstructured":"Artero, M., Biava, C., Amend, W., Tomlanovich, S. & Vincenti, F. Recurrent Focal Glomerulosclerosis - Natural-History and Response to Therapy. American Journal of Medicine 92, 375\u2013383 (1992).","journal-title":"American Journal of Medicine"},{"key":"50405_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/nep.12455","volume":"20","author":"M Maruyama","year":"2015","unstructured":"Maruyama, M. et al. Focal segmental glomerular sclerosis recurrence with massive proteinuria and anuria immediately after kidney transplantation. Nephrology (Carlton) 20, 93\u201395 (2015).","journal-title":"Nephrology (Carlton)"},{"key":"50405_CR43","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1016\/j.transproceed.2016.07.001","volume":"48","author":"A Kolonko","year":"2016","unstructured":"Kolonko, A., Piecha, G. & Wiecek, A. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report. Transplant Proc 48, 3092\u20133094 (2016).","journal-title":"Transplant Proc"},{"key":"50405_CR44","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2215\/CJN.07210810","volume":"6","author":"JM Hofstra","year":"2011","unstructured":"Hofstra, J. M., Beck, L. H. Jr., Beck, D. M., Wetzels, J. F. & Salant, D. J. Antiphospholipase A (2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6, 1286\u20131291 (2011).","journal-title":"Clin J Am Soc Nephrol"},{"key":"50405_CR45","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/TP.0b013e3182977ab1","volume":"96","author":"CRF Palacios","year":"2013","unstructured":"Palacios, C. R. F. et al. Urine But Not Serum Soluble Urokinase Receptor (suPAR) May Identify Cases of Recurrent FSGS in Kidney Transplant Candidates. Transplantation 96, 394\u2013399 (2013).","journal-title":"Transplantation"},{"key":"50405_CR46","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/ki.2013.55","volume":"84","author":"J Huang","year":"2013","unstructured":"Huang, J. et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 84, 366\u2013372 (2013).","journal-title":"Kidney Int"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50405-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50405-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50405-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:52:49Z","timestamp":1671267169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-50405-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,24]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["50405"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-50405-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,24]]},"assertion":[{"value":"3 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13783"}}